01 / Platform
Nanovia’s nano-immunoconjugates (NICs) combine a drug-loaded albumin nanoparticle with a noncovalent coating of targeting antibodies. This changes how the targeting antibody and therapeutic payload are brought together.1,2
Antibody Chemical linker Drug
Cell-directed targeting
A targeting antibody carries chemically linked drug molecules. In the conventional model shown in the comparison slide, the antibody binds a cancer-cell antigen and the conjugate is internalized for payload release.1
Antibody coating Albumin carrier Drug
Tumor-microenvironment targeting
An albumin nanoparticle carries the drug, with antibodies associated noncovalently on its surface. The AB160 prototype uses anti-VEGF targeting to guide delivery toward the tumor microenvironment.1,2
Simplified schematics, not to scale. The comparison describes delivery designs, not a head-to-head efficacy or safety study. ADC properties and NIC formulations vary.
Design differences
Key distinctions from the supplied ADC–NIC comparison, with formulation-specific context.6
| Design feature | Conventional ADC model | Nanovia NIC design |
|---|---|---|
| Antibody binding | One targeting antibodyThe slide emphasizes high affinity and two antigen-binding arms (Fab). | Multiple surface antibodiesMultivalent binding, with high- or low-affinity antibody designs described in the slide. |
| Antigen engagement | Single cell-surface antigenTargets a single cell-surface antigen at high density. | Multiple cell-surface antigensCan engage multiple cell-surface antigens at high or low density. |
| Payload capacity | Linker-attached payloadA limited number of highly potent drug molecules per antibody; loading varies by product. | Drug-loaded albumin carrierThe slide describes capacity for thousands of payload molecules within the nanoparticle architecture. |
| Cellular processing | Internalization-led deliveryIn the conventional model, uptake and lysosomal processing enable intracellular payload release. | Proposed low-pH releasePayload is released in the low-pH tumor microenvironment; no intracellular uptake of the intact NIC is required.6 |
| Assembly | Chemical conjugationLinker chemistry joins the antibody and payload. | Noncovalent coatingAntibodies associate with the albumin nanoparticle, supporting a modular assembly strategy.2 |
Higher loading and multivalent binding are architectural features—not measures of clinical benefit. Antigen requirements, release behavior, and bystander effects depend on the individual product or formulation.
The antibody determines the targeting strategy. AB160 targets extracellular VEGF in the tumor microenvironment; AR160 illustrates cell-bound targeting through CD20 on B cells. NICs are not limited to one type of target.1,3
Explore the evidenceAffinity describes the strength of a binding interaction. Valency describes the number of binding sites. The slide contrasts a conventional antibody’s two Fab arms with many antibodies on one particle. Drug-to-antibody ratio (DAR) and the number of drug molecules in a nanoparticle are different measures; no universal numerical range is assigned here.6
The slide proposes greater local bystander activity for NICs. That is a design concept, not a demonstrated class-wide advantage over ADCs. Some ADCs also exhibit bystander effects, and their loading and antigen requirements differ by product.6,7
The slide describes dissolution in an acidic tumor microenvironment. Separately, the published 2025 PD-L1 nanoparticle study reported stability at tested pH values of 5, 7, and 9, with dissociation into albumin–drug–antibody complexes and no detectable free chemotherapy drug under the reported conditions. The slide’s proposed low-pH mechanism is therefore not presented as a demonstrated feature of every NIC.5,6
The slide uses “highly toxic” and “low toxic” to describe payloads. Those descriptions do not establish a lower rate of adverse events in patients. Clinical safety and efficacy require formulation-specific evidence.
The comparison is adapted from the supplied platform materials. Published prototype studies provide the mechanistic context; investigational design concepts are not comparative clinical claims.
